Cemiplimab Libtayo

What it is

Cemiplimab is a fully human monoclonal antibody PD-1 immune checkpoint inhibitor used in the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. This immunotherapy agent has shown particular promise in patients with locally advanced or metastatic colorectal cancer harboring these specific biomarkers. Cemiplimab offers treatment options for patients whose tumors demonstrate high microsatellite instability, a condition found in approximately 15% of colorectal cancers that typically correlates with enhanced response to immune checkpoint blockade.

How it works

Cemiplimab works by binding to the programmed death receptor-1 (PD-1) on T-cells, blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2. This blockade prevents the immune system's natural "brakes" from being applied, allowing T-cells to maintain their activation and continue attacking cancer cells. In MSI-H colorectal tumors, which have high mutational burden and increased neoantigen presentation, this mechanism is particularly effective at restoring anti-tumor immune responses.

Molecular targets

Common side effects

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.